|
1
|
Eiró N, Altadill A, Juárez LM, Rodríguez
M, González LO, Atienza S, Bermúdez S, Fernandez-Garcia B,
Fresno-Forcelledo MF, Rodrigo L and Vizoso FJ: Toll-like receptors
3, 4 and 9 in hepatocellular carcinoma: Relationship with
clinicopathological characteristics and prognosis. Hepatol Res.
44:769–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shlomai A, de Jong YP and Rice CM: Virus
associated malignancies: The role of viral hepatitis in
hepatocellular carcinoma. Semin Cancer Biol. 26:78–88. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vescovo T, Refolo G, Vitagliano G, Fimia
GM and Piacentini M: Molecular mechanisms of hepatitis C
virus-induced hepatocellular carcinoma. Clin Microbiol Infect.
22:853–861. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jack CS, Arbour N, Manusow J, Montgrain V,
Blain M, McCrea E, Shapiro A and Antel JP: TLr signaling tailors
innate immune responses in human microglia and astrocytes. J
Immunol. 175:4320–4330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zughaier SM, Zimmer SM, Datta A, Carlson
RW and Stephens DS: Differential induction of the toll-like
receptor 4-MyD88-dependent and independent signaling pathways by
endotoxins. Infect Immun. 73:2940–2950. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mehmeti M, Allaoui R, Bergenfelz C, Saal
LH, Ethier SP, Johansson ME, Jirström K and Leandersson K:
Expression of functional toll like receptor 4 in estrogen
receptor/progesterone receptor-negative breast cancer. Breast
Cancer Res. 17:1302015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takazawa Y, Kiniwa Y, Ogawa E, Uchiyama A,
Ashida A, Uhara H, Goto Y and Okuyama R: Toll-like receptor 4
signaling promotes the migration of human melanoma cells. Tohoku J
Exp Med. 234:57–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Semlali A, Parine Reddy N, Arafah M,
Mansour L, Azzi A, Al Shahrani O, Al Amri A, Shaik JP, Aljebreen
AM, Alharbi O, et al: Expression and polymorphism of toll-like
receptor 4 and effect on NF-κB mediated inflammation in colon
cancer patients. PLoS One. 11:e01463332016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo XZ, He QZ and Wang K: Expression of
Toll-like receptor 4 in ovarian serous adenocarcinoma and
correlation with clinical stage and pathological grade. Int J Clin
Exp Med. 8:14323–14327. 2015.PubMed/NCBI
|
|
10
|
Shui IM, Stark JR, Penney KL, Schumacher
FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso
HD, et al: Genetic variation in the toll-like receptor 4 and
prostate cancer incidence and mortality. Prostate. 72:209–216.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang HY, Zhang ZJ, Cao CB, Wang N, Liu
FF, Peng JQ, Ren XJ and Qian J: The TLR4/NF-κB signaling pathway
mediates the growth of colon cancer. Eur Rev Med Pharmacol Sci.
18:3834–3843. 2014.PubMed/NCBI
|
|
12
|
Chen X, Zhao F, Zhang H, Zhu Y, Wu K and
Tan G: Significance of TLR4-MyD88 expression in breast cancer. Int
J Clin Exp Pathol. 8:7034–7039. 2015.PubMed/NCBI
|
|
13
|
Wang L, Zhu R, Huang Z, Li H and Zhu H:
Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer
cells promotes cell survival and proliferation in hepatocellular
carcinoma. Dig Dis Sci. 58:2223–2236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu WT, Jing YY, Yu GF, Han ZP, Yu DD, Fan
QM, Ye F, Li R, Gao L, Zhao QD, et al: Toll like receptor 4
facilitates invasion and migration as a cancer stem cell marker in
hepatocellular carcinoma. Cancer Lett. 358:136–143. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heinrich EL, Walser TC, Krysan K, Liclican
EL, Grant JL, Rodriguez NL and Dubinett SM: The inflammatory tumor
microenvironment, epithelial mesenchymal transition and lung
carcinogenesis. Cancer Microenviron. 5:5–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grivennikov SI: Inflammation and
colorectal cancer: Colitis-associated neoplasia. Semin
Immunopathol. 35:229–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawanishi S, Ohnishi S, Ma N, Hiraku Y,
Oikawa S and Murata M: Nitrative and oxidative DNA damage in
infection-related carcinogenesis in relation to cancer stem cells.
Genes Environ. 38:262017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rasic I, Radovic S and Aksamija G:
Relationship between chronic inflammation and the stage and
histopathological size of colorectal carcinoma. Med Arch.
70:104–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Langrish CL, Chen Y, Blumenschein WM,
Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and
Cua DJ: IL-23 drives a pathogenic T cell population that induces
autoimmune inflammation. J Exp Med. 201:233–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kolls JK and Lindén A: Interleukin-17
family members and inflammation. Immunity. 21:467–476. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toussirot É: The IL23/Th17 pathway as a
therapeutic target in chronic inflammatory diseases. Inflamm
Allergy Drug Targets. 11:159–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kortylewski M, Xin H, Kujawski M, Lee H,
Liu Y, Harris T, Drake C, Pardoll D and Yu H: Regulation of the
IL-23 and IL-12 balance by Stat3 signaling in the tumor
microenvironment. Cancer Cell. 15:114–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu D, Wu P, Huang Q, Liu Y, Ye J and Huang
J: Interleukin-17: A promoter in colorectal cancer progression.
Clin Dev Immunol. 2013:4363072013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin S: Primary Liver Cancer Diagnosis and
Treatment Expert Panel of the Chinese Ministry of Health:
Guidelines on the diagnosis and treatment of primary liver cancer
(2011 edition). Chin Clin Oncol. 1:2304–3865. 2012.
|
|
25
|
Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen
JY, Chen J, Ruan DY, Lin Q, Dong M, et al: Validation and ranking
of seven staging systems of hepatocellular carcinoma. Oncol Lett.
14:705–714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song Y, Zhou M, Cao Y, Qi J, Geng J and
Liu X: Expression of GLP-1 receptor and CD26 in human thyroid
C-cells: The association of thyroid C-cell tumorigenesis with
incretin-based medicine. Oncol Lett. 13:2684–2690. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ruifeng G, Yunhe F, Zhengkai W, Ershun Z,
Yimeng L, Minjun Y, Xiaojing S, Zhengtao Y and Naisheng Z:
Chlorogenic acid attenuates lipopolysaccharide-induced mice
mastitis by suppressing TLR4-mediated NF-κB signaling pathway. Eur
J Pharmacol. 729:54–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Langowski JL, Zhang X, Wu L, Mattson JD,
Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M:
IL-23 promotes tumour incidence and growth. Nature. 442:461–465.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou Y, Wu PW, Yuan XW, Li J and Shi XL:
Interleukin-17A inhibits cell autophagy under starvation and
promotes cell migration via TAB2/TAB3-p38 mitogen-activated protein
kinase pathways in hepatocellular carcinoma. Eur Rev Med Pharmacol
Sci. 20:250–263. 2016.PubMed/NCBI
|
|
31
|
Sakurai T, Kashida H, Watanabe T, Hagiwara
S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J and
Kudo M: Stress response protein cirp links inflammation and
tumorigenesis in colitis-associated cancer. Cancer Res.
74:6119–6128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Liu J, Hu X, Liu S and He B:
Prognostic and therapeutic values of tumor necrosis factor-alpha in
hepatocellular carcinoma. Med Sci Monit. 22:3694–3704. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grivennikov SI, Wang K, Mucida D, Stewart
CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung
KE, et al: Adenoma-linked barrier defects and microbial products
drive IL-23/IL-17-mediated tumour growth. Nature. 491:254–258.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blauvelt A, Lebwohl MG and Bissonnette R:
IL-23/IL-17A dysfunction phenotypes inform possible clinical
effects from anti-IL-17A therapies. J Invest Dermatol.
135:1946–1953. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
González-Reyes S, Marín L, González L,
González LO, del Casar JM, Lamelas ML, González-Quintana JM and
Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and
their association with metastasis. BMC Cancer. 10:6652010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kulig P, Burkhard S, Mikita-Geoffroy J,
Croxford AL, Hövelmeyer N, Gyülvészi G, Gorzelanny C, Waisman A,
Borsig L and Becher B: IL17A-mediated endothelial breach promotes
metastasis formation. Cancer Immunol Res. 4:26–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Teng MW, Bowman EP, McElwee JJ, Smyth MJ,
Casanova JL, Cooper AM and Cua DJ: IL-12 and IL-23 cytokines: From
discovery to targeted therapies for immune-mediated inflammatory
diseases. Nat Med. 21:719–729. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brentano F, Ospelt C, Stanczyk J, Gay RE,
Gay S and Kyburz D: Abundant expression of the interleukin (IL)23
subunit p19, but low levels of bioactive IL23 in the rheumatoid
synovium: Differential expression and Toll-like receptor-(TLR)
dependent regulation of the IL23 subunits, p19 and p40, in
rheumatoid arthritis. Ann Rheum Dis. 68:143–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
